Reports Q4 revenue $28M, consensus $17.83M. "Agenus has entered 2023 with strong momentum across our extensive and diverse clinical pipeline of immuno-oncology programs. Our anchor programs, botensilimab and balstilimab show exciting potential in combination to treat a broad spectrum of treatment-resistant cancers," said Garo Armen, CEO. "With the growing body of data demonstrating robust, consistent, and durable efficacy signals from a trial of over 300 patients across nine metastatic, late-line cancers, we are expediting the expansion of our botensilimab/balstilimab development program in MSS CRC and other priority indications."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AGEN:
- Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
- Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
- Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
- Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
- Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
